Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Chairman operating in the Therapeutics space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Gabriel Mecklenburg
Co-founder, Executive Chairman of Hinge Health
Follow Gabriel Mecklenburg:
About Hinge Health: Hinge Health is a patient-centered digital clinic for treating chronic musculoskeletal conditions.
Quentin Pankhurst
Chairman of MediSieve
Quentin is a world expert in magnetic nanoparticles, and an academic innovator with direct experience in the medical technology sector. In 2007, he founded Endomagnetics to commercialise a device for sentinel node detection in breast cancer, serving the company as CEO until 2010 and as a board member until 2014. He played a key role in CE marking the device, which has treated more than 3,500 patients in 15 countries. A physicist by training, Quentin is the Director of the Healthcare Biomagnetics Laboratory at UCL, where he runs programmes in bio- and nanomagnetism aimed at making practicle advances in the use of magnetic nanoparticles in healthcare. He is a champion of translational R&D, for which he established the UCL Institute of Biomedical Engineering. The objective of the IBME is to bring together UCL’s excellence in academic and clinical R&D – around a thousand staff, fellows, nurses and students in 35 different centres, departments and institutes – to create the world’s best research centre for biomedical engineering.
Follow Quentin Pankhurst:
About Endomag, University College London (UCL): MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Brendan McNutt
Founder and Chairman of Bryn Melyn Care
Follow Brendan McNutt:
About Bryn Melyn Care: Bryn Melyn Care is a leading provider of therapeutic residential care, independent education, and integrated clinical services.
Ken Powell
Executive Chairman of the Board of ReViral
Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-Chip a Cardiff, Wales based life science company developing novel delayed release formulations of drugs (merged with Midatech and the joint company listed on AIM in 2015). Founder and CEO of Arrow Therapeutics Ltd (a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007). Professor at UCL and Deputy Director of the Wolfson Institute for Biomedical Research where he had responsibility for commercial activity including setting up five biotechnology start-up companies. He was a senior Pharmaceutical executive with the Wellcome Foundation which he decided to leave at the Wellcome/Glaxo merger. He has had a successful academic career in the UK and USA. He is an expert virologist and has been involved in the development of multiple drugs including anti-viral compounds against herpes viruses, HIV, Hepatitis C and RSV.
Follow Ken Powell:
About ReViral: ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
Robert Thong
Chairman & Chief Executive Officer of Multiomic Health
Robert has made the art of consulting his life’s work. As Co-Founder and Executive Chairman of Unleash, he applies a wealth of experience to his personal mission: creating world-beating organisations. A supportive advisor to senior executives, Robert combines experienced know-how with an open mindset, delivering results that keep his clients coming back for more. Moving to the UK from Malaysia as a super-smart, teenage maths whiz, Robert started his career as an actuary. Finding business more interesting than statistical models, it wasn’t long before he decided to pursue the MBA that would introduce him to the world of management consulting. Initially focusing on analytical strategy development and operations improvement across various industries, Robert was soon drawn towards managing strategic change in R&D-driven organisations. Robert’s deep understanding of the inner workings of the pharmaceutical industry combined with his appreciation of a senior executive’s daily pressures, is a rare find indeed. He has not only been the pharmaceutical practice head in major consultancies, held P&L accountability and board positions, Robert has also spent much of his time on the ground understanding the real-life issues facing clients in laboratories, factories, pharmacies and physician offices. Coming from an analytical background himself, Robert had to learn in practice about the importance of managing change and engaging people to ensure lasting results, and was inspired to help clients do the same. Robert is dedicated to his clients winning long-term. After founding a boutique consultancy focused on the management practices of small-to-mid sized outfits competing with Big Pharmas, he decided to follow his true calling: guiding leaders and organisations of all types and sizes to success through people-driven strategy execution.
Follow Robert Thong:
About Multiomic Health, Selvedge Venture: Multiomic Health is building a precision therapeutics discovery platform for metabolic syndrome diseases
Huw Jones
Chief Executive Officer & Executive Chairman of Chronos Therapeutics
Follow Huw Jones:
About Chronos Therapeutics, Evgen Pharma: Chronos Therapeutics is a drug development company focused on the development of drugs for the treatment of age-related diseases.
Bill Potter
Executive Chairman of Futura Medical
William Potter became Chairman in June 2001. He is an adviser to the Nominations Committee and to the Remuneration Committee. He provides advice and expertise on product development matters bringing to bear his considerable experience. He has over 30 years of experience in research and development including bringing new products to market involving a wide range of medical devices. He has extensive knowledge of worldwide regulatory procedures, intellectual property issues and licensing. Dr Potter previously worked at London International Group plc, including seven years as Group Scientific Affairs Director, and at Smith & Nephew plc.
Follow Bill Potter:
About Futura Medical: Futura’s innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced
Sheraz Daya
Founder, Chairman & Medical Director of Centre for Sight
Follow Sheraz Daya:
About Centre for Sight: Centre for Sight provides eye care services, from basic diagnostic and therapeutic services to complex operative procedures.
